Over the weekend Gilead announced that it has agreed to purchase cancer-drug company Immunomedics for $21 billion. Shares of Immunomedics, which sells Trodelvy, a drug used to treat different forms of breast cancer, were exploding on Monday as the market re-opened. The stock soared as much as 106%. Trodelvy is also being evaluated for a … Continue reading “Gilead to Buy Cancer-drug Company Immunomedics for $21B”
